Vor Biopharma Announces Positive Phase 3 Trial Results for Telitacicept in Lupus, Published in NEJM
Vor Biopharma Inc. has announced the publication of results from a Phase 3 clinical study evaluating telitacicept in patients with systemic lupus erythematosus $(SLE)$ in The New England Journal of Medicine. The study, conducted at 42 hospitals in China and sponsored by RemeGen Co., Ltd., included 335 patients with active SLE despite standard therapy. Telitacicept demonstrated a statistically significant improvement in disease activity, with 67.1% of patients achieving a modified SLE Responder Index-4 (SRI-4) response at week 52, compared to 32.7% in the placebo group (P<0.001). Additional secondary measures, such as SELENA-SLEDAI score reduction, also favored telitacicept. The results have already been presented through publication in a peer-reviewed journal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546514-en) on October 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。